Introduction
In the USA, harms associated with opioid dependence have paralleled the increasing prescription of strong opioids. 1 From 1999 to 2015, more than 183,000 deaths have been attributed to prescription opioids, and opioid abuse is a major cause of disability. 2, 3 Over this period, increased opioid prescribing and drug-related deaths have also been seen in the UK. 4, 5 As prescribers and the public become increasingly aware of the potential risk of opioid dependence, the pharmacological management of chronic pain has never been under greater scrutiny. Chronic pain affects between a third and a half of the UK population and the moral imperative to treat pain has likely provoked the rise in opioid use. 6, 7 UK guidelines for the management of chronic lower back pain recommend a step-wise approach to pharmacological management, and weak opioids are only considered if a NSAID is contraindicated or has been ineffective. 8 Unfortunately, however, many non-opioid analgesics have limited utility in clinical practice (for example, NSAIDs are a common cause of adverse drug reactions resulting in hospitalisation). 9 It is understandable that prescribers would attempt using a non-NSAID, non-opioid analgesic in response to the twin pressures of an opioid epidemic and the burden of chronic pain. Changing prescribing practice in Scotland has resulted in a proportional increase in the prescription of strong opioids, but also growing use of the non-opioid analgesics gabapentin and pregabalin. 10 In the UK, gabapentin and pregabalin prescribing has increased by 350% and 150% over 5 years, respectively. 11 This trend is likely due to avoidance of opioid analgesics, 12 despite the use of gabapentin and pregabalin for non-neuropathic pain being unlicensed and ineffective. Patients inappropriately prescribed gabapentin or pregabalin may not benefi t and may be exposed to potential harms, which broadly fall into two categories. First, by causing an adverse drug reaction or toxicity, e.g. central nervous system effects (headache, visual disturbance, drowsiness, agitation, delirium, lethargy); cardiac effects (tachycardia, bradycardia); disturbances in muscle control and movement, and gastrointestinal symptoms. Second, gabapentin or pregabalin prescription may result in drug misuse or diversion (the transfer of any legally prescribed substance from the individual for whom it was prescribed to another person for illicit use).
History of gabapentin and pregabalin
Gabapentinoids are close analogues of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Our review is restricted to gabapentin and pregabalin, which are effective in the treatment of neuropathic pain. 13 Their mechanism of action appears to be unrelated to direct effects on the GABAergic system, and their benefi cial effect is exerted through modifi cation of the alpha2-subunit of voltage gated calcium channels. of post-herpetic neuralgia. Despite this limited indication, off-label prescribing of gabapentin for other pain syndromes increased in the 1990s, a phenomenon largely attributable to extensive marketing campaigns in the USA, and assumed safety. 15, 16 Ultimately, Pfizer subsidiary Warner-Lambert admitted to violation of US Federal regulations by promoting the drug for pain, psychiatric and other unapproved conditions. Pregabalin was approved for treating diabetic neuropathy and post-herpetic neuralgia in 2004 and is now available as a generic medication.
What are the indications for gabapentinoids?
In the UK, gabapentinoids are currently licensed for the treatment of focal seizures and peripheral neuropathic pain. Pregabalin is also indicated for use in central neuropathic pain and generalised anxiety disorder. The increased use of these drugs cannot be fully explained by increasing prevalence of their licensed indications. A UK study in primary care noted that almost two-thirds of pregabalin prescriptions did not have a diagnostic code corresponding to an approved indication. 17 Healthcare professionals should be aware of their greater responsibilities when prescribing off-label medicines, in comparison to a licensed drug. 18 Prescribers must be satisfi ed that such use would better serve the patient's needs than an appropriately licensed alternative, including confi dence in the balance between the potential benefi t and the risk of harms.
What is the current evidence for the use of gabapentinoids in pain management?
Gabapentinoids are considered to be effective for neuropathic pain. Consequently, both gabapentin and pregabalin are recommended by the National Institute for Health and Care Excellence for this indication. 19 Cochrane reviews provide a similar conclusion with regard to their effi cacy, noting 3 or 4 out of 10 participants achieved a greater than 50% reduction in neuropathic pain with gabapentin, compared with 1 or 2 out of 10 for placebo. 20 Prescribers should be aware that over half of those treated with gabapentin do not have worthwhile pain relief but may instead experience adverse effects. Similar issues affect pregabalin, a treatment which will substantially benefi t only a minority of patients with neuropathic pain. 21 Prescribers should also be aware of the evidence base from which this advice is derived; direct evidence of benefi t only exists in diabetic neuropathy and herpetic neuralgia. Extrapolation of presumed benefi t from this narrow subset of patients may not accurately refl ect 'real world' benefi t for other causes of neuropathic pain.
A wide range of off-label, non-neuropathic pain uses have been proposed for gabapentinoids but these come with a limited evidence base that is underpowered and/or from studies open to bias. 8, 22 Notably, in the majority of reports promoting the benefi ts of off-label use, gabapentin is not the optimal treatment. 23 Existing evidence for the use of gabapentinoids in chronic lower back pain demonstrates the risk of adverse effects without any clear benefi t.
24 Surprisingly, there is inconsistent evidence of benefi t even if chronic back pain is related to radiculopathy. 25 Pregabalin is licensed for the management of fi bromyalgia in the USA but not in the UK. Pregabalin produces a major reduction in pain intensity events for a small proportion of people (about 10% more than placebo), similar to other licensed medicines in fi bromyalgia (milnacipran, duloxetine). 26 There is insuffi cient evidence to support the use of gabapentin in fi bromyalgia. 27 In other chronic pain syndromes, e.g. chronic pain due to chronic pancreatitis, short-term use of pregabalin may decrease short-term opioid use and short-term pain scores, but increases rates of adverse events compared to placebo. 28 Effi cacy of gabapentinoids in acute pain management has also been investigated, yet opinions remain divided about their clinical effectiveness. Superfi cially positive trials supporting the use of gabapentin in postoperative pain reveal a high number-needed-to treat, suggesting limited clinical utility and poor performance in comparison to alternative analgesics, i.e. NSAIDs and paracetamol. 29 Interestingly, postoperative gabapentinoid use may reduce total morphine consumption and morphine-related complications (nausea and itch) at the risk of increased sedation and visual disturbance. 30, 31 There is no evidence to suggest gabapentinoids reduce the risk of postoperative chronic pain. 32 
Patterns of misuse
Gabapentin was originally considered to have no misuse potential, an assumed attribute that likely contributed to high rates of off-label prescribing. 16 While meaningful modulation of the dopaminergic reward pathway is yet to be proven, GABA inhibits the release of excitatory neurotransmitters, explaining the anxiolytic and sleep-modifying activities of gabapentinoids. 33 Reports of harm related to gabapentinoids are currently few, in comparison to opioids, yet the increasing trend in mortality is concerning in the face of their increasing availability. Between 2013 and 2015 in the UK, deaths reported to involve gabapentinoids increased by almost 400%, from 36 to 137. 34, 35 Misuse is defi ned as use of a substance for a purpose not consistent with legal or medical guidelines, such as taking another person's medication or taking a higher dosage than prescribed. 36 Current estimates suggest 1% of the general population misuse gabapentin, as do 15-22% of people who misuse opioids, and 40-65% of people with gabapentinoid prescriptions. 37 Reports of misuse normalised to prescription number would suggest that drug dependence issues are more frequently reported with pregabalin than gabapentin 22 and cases of pregabalin misuse are increasing. 38 Pregabalin may have a higher misuse potential than gabapentin due to its rapid absorption and faster onset of action. 39 The issues underpinning misuse of gabapentinoids are not yet fully understood. Unsurprisingly, known substance misuse is associated with misuse of pregabalin. 22, 40, 41 Opioid users report that pregabalin reinforces the effects of opioids and reduces the undesirable effects of withdrawal symptoms, EE Morrison, EA Sandilands, DJ Webb making it widely sought after for misuse. 35, 42 Opioid treatment programmes have reported approximately 10% of patients test positive for pregabalin, the majority of whom were not prescribed this medication. 43, 44 Co-misuse of gabapentinoids and opioids is particularly concerning because high-dose pregabalin may exaggerate the respiratory depression seen with opioid use. 35 Seventy-nine percent of deaths attributed to gabapentinoids also involved opioids. This statistic may refl ect causation due to worsened respiratory depression or an association made at post-mortem due to the increasing co-misuse with opioids. 35 The misuse of gabapentinoids is well described in the prison population. In February 2015, UK prisons reported high numbers of prisoners being prescribed gabapentinoids in a manner not in keeping with best clinical practice. 34 Due to the high potential for diversion, some prisons refuse to prescribe pregabalin. This leads to inequality between care in prison and the community, and resulted in prisoners reporting inadequate pain management. 45 As we become increasingly aware of the potential harm associated with gabapentinoids, several countries have acted in an attempt to reduce harm from diversion. Pregabalin is placed under Schedule 5 of the US Controlled Substances Act and was listed as a new recreational psychoactive substance by the relevant EU agencies in 2010. 42 In January 2016, the UK Advisory Council for the Misuse of Drugs recommended that both pregabalin and gabapentin should be controlled under the Misuse of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drug Regulations 2001 as Schedule 3 (actions that will not preclude legitimate use on prescription). 34 This recommendation has been accepted in principle by the Minister for Vulnerability, Safeguarding and Countering Extremism, pending public consultation. 46 
Conclusion
Ongoing use of gabapentinoids in the management of chronic pain is driven primarily by the imperative to treat this disabling condition, with a lack of good alternatives and the perception these drugs are safe. Emerging evidence of lack of effectiveness appears to have had little impact on prescribing practice. 16 Within chronic pain management, patient and prescriber expectation is high; advocating maximum possible pain relief for every patient in pain. 47 What opioids and gabapentinoids have in common is their anxiolytic and dissociative effects, addressing comorbid issues often associated with chronic pain. [48] [49] [50] Improvements in a patient's quality of life may not be mediated entirely through pain relief but linked to pregabalin's effects on sleep disturbance and anxiety. 51 Consequently, judging the effectiveness of gabapentinoids for pain control may be diffi cult as they may have positive consequences on a comorbid anxiolytic element. While addressing psychological factors is important in chronic pain, gabapentinoids are not the best approach. 52 The burden caused by harm and diversion of gabapentinoids is increasingly under scrutiny. We must be confident our prescribing decisions will be to the overall benefi t of our patients. Similar to the ongoing opioid crisis, we as prescribers must be conscious of the potential to do harm, both to our patients and society as a whole.
